Right now what we can say is in multiple post hoc analyses of randomized clinical trials, as well as now large real-world data from the Ironman registry, that if you have a PSA over 0.2, that has a poor prognosis. That’s information that can be given to patients. It does not imply right now that anything should be done about that situation, simply because I think that’s the role of clinical trials to really understand if we should be adding on more therapy or not...
Right now what we can say is in multiple post hoc analyses of randomized clinical trials, as well as now large real-world data from the Ironman registry, that if you have a PSA over 0.2, that has a poor prognosis. That’s information that can be given to patients. It does not imply right now that anything should be done about that situation, simply because I think that’s the role of clinical trials to really understand if we should be adding on more therapy or not. I think at the same time, if you look at patients that have PSA that’s very low, PSA that is, say, under 0.1 or under 0.02, you know, these patients are faring very well. Do we need as much therapy as we’re giving? Again, that does not imply that we should be stopping patients’ therapy, but we should be studying how it’s safe to do those kind of approaches.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
